SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

DNTH

Dianthus Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The early GO decision in CAPTIVATE de-risks the CIDP program and supports upcoming Phase 3 initiation in gMG. With multiple near-term catalysts (MMN data in 2H'26, gMG trial start, DNTH212 data), the stock may re-rate on continued clinical execution. Monitor Part B guidance for CAPTIVATE by YE'26.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.23
T+0 close · Mar 9, 2026 · via day close
Latest settled
+2.95%
T+60 · $81.57
Vs SPY
−9.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $79.23entry
  2. T+1 · 8mo ago +9.71%α +9.89% · $86.92
  3. T+5 · 8mo ago −1.55%α −0.20% · $78.00
  4. T+20 · 7mo ago +8.80%α +11.60% · $86.20
  5. T+60 · 6mo ago +2.95%α −9.03% · $81.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP, based on achieving 20 confirmed responders in the interim analysis. The company has $514.4 million in cash, providing a runway into 2028, despite a widening net loss driven by increased R&D spending. Top-line data from multiple late-stage trials are expected in 2026–2028.

Key Financial Metrics

Revenue
$2.0M
-67.3% YoY
EPS
$-4.20

Key Facts

  • Achieved early GO decision in Phase 3 CAPTIVATE trial for CIDP based on 20 confirmed responders with less than 40 participants completing Part A.
  • Phase 3 trial in gMG expected to initiate mid-2026 with top-line results in 2H'28.
  • Phase 2 MoMeNtum trial in MMN on track for top-line results in 2H'26.
  • Phase 1 data for DNTH212 in healthy volunteers expected in 2H'26.
  • Cash position of $514.4 million as of December 31, 2025, sufficient to fund operations into 2028.
  • R&D expenses increased to $145.6 million in 2025 from $83.1 million in 2024, primarily due to clinical development and headcount growth.
  • Net loss for 2025 was $162.3 million ($4.20 per share), up from $85.0 million ($2.55 per share) in 2024.

Financial Impact

Increased R&D spend by $62.5 million YoY; net loss nearly doubled to $162.3 million. Cash runway extended to 2028 despite higher burn.

r_and_d_expensenet_losscash_runway

Risk Factors

  • Interim data from open-label Part A of CAPTIVATE is not randomized or controlled; final results may differ.
  • No revenue from product sales; reliant on capital markets for future funding beyond 2028.
  • Increased stock-based compensation contributing to higher G&A and R&D expenses.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251709

Track record

23 reports on DNTH

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026